{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:32:55Z","timestamp":1793082775233,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejphar.2026.179406","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T06:43:43Z","timestamp":1791441823000},"page":"179406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases"],"prefix":"10.1016","volume":"1037","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3689-3079","authenticated-orcid":false,"given":"Elena","family":"Koceva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5667","authenticated-orcid":false,"given":"Gert N.","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179406_bib1","series-title":"Molecular Biology of the Cell","author":"Alberts","year":"2014"},{"key":"10.1016\/j.ejphar.2026.179406_bib2","first-page":"59","article-title":"Molecular pharmacology of glucagon-like peptide 1-based therapies in the management of type two diabetes mellitus and obesity","volume":"14","author":"Alzahrani","year":"2025","journal-title":"Integrated Pharm. Res. Pract."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179406_bib3","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"Pioneer 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib5","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194752","article-title":"Signalling architecture of the glucagon-like peptide-1 receptor","volume":"136","author":"Austin","year":"2026","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 receptor expression within the human heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"issue":"18","key":"10.1016\/j.ejphar.2026.179406_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf7737","article-title":"Divergent acute versus prolonged pharmacological GLP-1R responses in adult \u03b2 cell- specific \u03b2-arrestin 2 knockout mice","volume":"9","author":"Bitsi","year":"2023","journal-title":"Sci. Adv."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000097","article-title":"Agonist-induced membrane nanodomain clustering drives GLP-1 receptor responses in pancreatic beta cells","volume":"17","author":"Buenaventura","year":"2019","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/db17-0639","article-title":"A targeted RNAi screen identifies endocytic trafficking factors that control GLP-1 receptor signalling in pancreatic \u03b2-cells","volume":"67","author":"Buenaventura","year":"2018","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179406_bib11","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s00125-004-1379-6","article-title":"Glucagon-like peptide-1 prevents beta cell glucolipotoxicity","volume":"47","author":"Buteau","year":"2004","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2026.179406_bib13","article-title":"Effects of CT-388, a once-weekly signalling-biased dual GLP-1\/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity","volume":"103","author":"Chakravarthy","year":"2026","journal-title":"Mol. Met."},{"issue":"13","key":"10.1016\/j.ejphar.2026.179406_bib14","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41591-025-04027-5","article-title":"The global macroeconomic burden of diabetes mellitus","volume":"32","author":"Chen","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.179406_bib16","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ceb.2016.03.021","article-title":"N-linked glycosylation and homeostasis of the endoplasmic reticulum","volume":"41","author":"Cherepanova","year":"2016","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejphar.2026.179406_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2025.107553","article-title":"Hypothalamic regulation of obesity: revealing the therapeutic potential of a novel anti-obesity peptide","volume":"161","author":"Choo","year":"2025","journal-title":"Vascul. Pharmacol"},{"key":"10.1016\/j.ejphar.2026.179406_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2026.179406_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101352","article-title":"Time and metabolic state-dependent effects of GLP-1R agonists on NPY\/AgRP and POMC neuronal activity in vivo","volume":"54","author":"Dong","year":"2021","journal-title":"Mol. Metabol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.pharmthera.2006.11.007","article-title":"Mechanisms of action of glucagon-like peptide 1 in the pancreas","volume":"113","author":"Doyle","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2362.1992.tb01464.x","article-title":"Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man","volume":"22","author":"Eissele","year":"1992","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2026.179406_bib27","doi-asserted-by":"crossref","first-page":"8404","DOI":"10.3390\/ijms21218404","article-title":"Ligand-specific factors influencing GLP-1 receptor post-endocytic trafficking and degradation in pancreatic beta cells","volume":"21","author":"Fang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1677\/joe.1.06160","article-title":"Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signallingpathways","volume":"188","author":"Friedrichsen","year":"2006","journal-title":"J. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib30","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib32","first-page":"835","article-title":"Pharmaceutical analytical profile for novel SGL-2 inhibitor: dapagliflozin","volume":"51","author":"Ganorkar","year":"2021","journal-title":"Crit. Rev. Anal. Chem."},{"issue":"10402","key":"10.1016\/j.ejphar.2026.179406_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2026.179406_bib34","article-title":"Effect of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on myocardial infarction and stroke in type 2 diabetes: a systematic review and meta- analysis","author":"Ghafoury","year":"2026","journal-title":"Diabetes Ther., online ahead of print"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib36","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41574-019-0168-8","article-title":"Function and mechanisms of enteroendocrine cells and gut hormones in metabolism","volume":"15","author":"Gribble","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"7","key":"10.1016\/j.ejphar.2026.179406_bib37","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes.Metab."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib38","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1210\/jc.2017-02006","article-title":"Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans","volume":"103","author":"Halim","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib39","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1210\/en.2007-1743","article-title":"Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like peptide-1 receptor stimulation","volume":"149","author":"Hayes","year":"2008","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib40","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2213-8587(22)00085-7","article-title":"Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial","volume":"10","author":"Heise","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib41","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.2337\/db10-0128","article-title":"Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like peptide 1 neurons","volume":"59","author":"Hisadome","year":"2010","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib42","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"issue":"23","key":"10.1016\/j.ejphar.2026.179406_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn5345","article-title":"Glucose-sensing glucagon-like peptide-1 receptor neurons in the dorsomedial hypothalamus regulate glucose metabolism","volume":"8","author":"Huang","year":"2022","journal-title":"Sci. Adv."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179406_bib44","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf125","article-title":"Glucagon-like peptide 1 (GLP-1) action on hypothalamic feeding circuits","volume":"166","author":"Hwang","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2026.179406_bib45","series-title":"Diabetes Atlas","year":"2025"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179406_bib46","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/s41366-025-01859-6","article-title":"Gastrointestinal adverse events associated with GLP-1RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis","volume":"49","author":"Ismaiel","year":"2025","journal-title":"Int. J. Obes. (Lond.) (2005)"},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib47","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"New Engl. J. Med."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179406_bib49","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179406_bib50","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016334","article-title":"Genetic and biased agonist-mediated reductions in \u03b2-arrestin recruitment prolong cAMP signalling at glucagon family receptors","volume":"296","author":"Jones","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib51","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/biom15060796","article-title":"Retatrutide - a game changer in obesity pharmacotherapy","volume":"15","author":"Katsi","year":"2025","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.104690","article-title":"The ubiquitination status of the glucagon receptor determines signal bias","volume":"299","author":"Kaur","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.179406_bib53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diabetes.52.2.380","article-title":"The influence of GLP-1 on glucose-induced insulin secretion: effect on \u00df-cells sensitivity in type 2 and non-diabetic subjects","volume":"52","author":"Kjems","year":"2003","journal-title":"Diabetes"},{"issue":"10403","key":"10.1016\/j.ejphar.2026.179406_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2026.179406_bib55","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","article-title":"Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor","volume":"318","author":"Knudsen","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms27041886","article-title":"The multifaceted nature of GLP-1: molecular mechanisms and signalling pathways in metabolic and neurodegenerative diseases","volume":"27","author":"Kowalska","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib57","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db15-0973","article-title":"Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia","volume":"65","author":"Krieger","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2026.179406_bib58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.peptides.2017.03.004","article-title":"Semi- microbiological synthesis of an active lysinoalanine-bridged analog of glucagon-like- peptide-1","volume":"91","author":"Kuipers","year":"2017","journal-title":"Peptides"},{"issue":"24","key":"10.1016\/j.ejphar.2026.179406_bib59","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179406_bib60","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib61","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/BCJ20180853","article-title":"Endothelin-converting enzyme-1 regulates glucagon-like peptide-1 receptor signalling and resensitisation","volume":"476","author":"Lu","year":"2019","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib62","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1021\/jm500810s","article-title":"Glucagon-like peptide-1 (GLP-1) analogs: recent advances, new possibilities, and therapeutic implications","volume":"58","author":"Manandhar","year":"2015","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib63","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet. Med."},{"issue":"19","key":"10.1016\/j.ejphar.2026.179406_bib64","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179406_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.678055","article-title":"The interplay of glucagon-like peptide-1 receptor trafficking and signalling in pancreatic beta cells","volume":"12","author":"Marzook","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib67","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2337\/db23-0356","article-title":"Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes","volume":"73","author":"Mashayekhi","year":"2024","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.ejphar.2026.179406_bib68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","article-title":"Efficacy and safety of once-weekly semaglutide 2\u00b74 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial","volume":"12","author":"McGowan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2026.179406_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116119","article-title":"The role of G protein-coupled receptor kinases in GLP-1R \u03b2-arrestin recruitment and internalisation","volume":"222","author":"McNeill","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179406_bib71","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2337\/db09-1899","article-title":"Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?","volume":"59","author":"Meier","year":"2010","journal-title":"Diabetes"},{"issue":"1\u20133","key":"10.1016\/j.ejphar.2026.179406_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(02)00039-3","article-title":"Gastric inhibitory polypeptide: the neglected incretin revisited","volume":"107","author":"Meier","year":"2002","journal-title":"Regul. Pept."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib74","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas","volume":"79","author":"Mojsov","year":"1987","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.ejphar.2026.179406_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179406_bib76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metabol."},{"issue":"17","key":"10.1016\/j.ejphar.2026.179406_bib77","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1021\/jm100602m","article-title":"Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges","volume":"53","author":"Murage","year":"2010","journal-title":"J. Med. Chem."},{"issue":"51","key":"10.1016\/j.ejphar.2026.179406_bib78","doi-asserted-by":"crossref","first-page":"11000","DOI":"10.1021\/acs.jpcb.3c05930","article-title":"Palmitoylation of the glucagon-like peptide-1 receptor modulates cholesterol interactions at the receptor-lipid microenvironment","volume":"127","author":"Naglekar","year":"2023","journal-title":"J. Physiol. Chem. B"},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib79","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib80","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib81","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"issue":"Suppl. 4","key":"10.1016\/j.ejphar.2026.179406_bib82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179406_bib83","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1172\/JCI140046","article-title":"Gs\/Gq signalling switch in \u03b2 cells defines incretin effectiveness in diabetes","volume":"130","author":"Oduori","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2026.179406_bib84","article-title":"The role of SGLT2 inhibitors in the prevention of type 2 diabetes: a narrative review of current evidence","author":"Owczarczyk-Durma","year":"2026","journal-title":"Diabetes Ther., online ahead of print"},{"issue":"12","key":"10.1016\/j.ejphar.2026.179406_bib85","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41387-025-00397-4","article-title":"Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy","volume":"15","author":"Peri","year":"2025","journal-title":"Nutr. Diabetes"},{"key":"10.1016\/j.ejphar.2026.179406_bib87","doi-asserted-by":"crossref","first-page":"401","DOI":"10.2147\/TCRM.S7313","article-title":"Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide","volume":"6","author":"Pinkney","year":"2010","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib88","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molmet.2015.01.010","article-title":"Chronic hyperglycemia downregulates GLP-1 receptor signalling in pancreatic \u03b2-cells via protein kinase A","volume":"4","author":"Rajan","year":"2015","journal-title":"Mol. Metabol."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib90","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","article-title":"Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation","volume":"37","author":"Ravussin","year":"2025","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.ejphar.2026.179406_bib91","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib92","article-title":"Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R\/GIPR biased agonism yielding greater efficacy","volume":"6","author":"Rodriguez","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"10295","key":"10.1016\/j.ejphar.2026.179406_bib93","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejphar.2026.179406_bib94","doi-asserted-by":"crossref","first-page":"11340","DOI":"10.1074\/jbc.M708740200","article-title":"Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain","volume":"283","author":"Runge","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.179406_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as alzheimer's and Parkinson'S disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2026.179406_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/JCI146353","article-title":"GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice","volume":"131","author":"Samms","year":"2021","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2026.179406_bib97","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.neuint.2019.04.010","article-title":"GLP-1: molecular mechanisms and outcomes of a complex signalling system","volume":"128","author":"Smith","year":"2019","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib98","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","article-title":"Novel GLP-1-based medications for type 2 diabetes and obesity","volume":"47","author":"Son","year":"2026","journal-title":"Endocr. Rev."},{"issue":"4","key":"10.1016\/j.ejphar.2026.179406_bib99","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"7258","key":"10.1016\/j.ejphar.2026.179406_bib100","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179406_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1398059","article-title":"Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity","volume":"11","author":"Tamayo-Trujillo","year":"2024","journal-title":"Front. Nutr."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib102","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib103","doi-asserted-by":"crossref","first-page":"7410","DOI":"10.1038\/srep07410","article-title":"The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression","volume":"4","author":"Thompson","year":"2014","journal-title":"Sci. Rep."},{"issue":"Suppl. 2","key":"10.1016\/j.ejphar.2026.179406_bib104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes. Metabol."},{"issue":"10","key":"10.1016\/j.ejphar.2026.179406_bib105","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib107","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.molmet.2014.04.009","article-title":"Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection","volume":"3","author":"Ussher","year":"2014","journal-title":"Mol. Metabol."},{"issue":"2","key":"10.1016\/j.ejphar.2026.179406_bib108","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/molecules28020751","article-title":"GLP-1R signalling and functional molecules in incretin therapy","volume":"28","author":"Wan","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"10","key":"10.1016\/j.ejphar.2026.179406_bib109","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/clinem\/dgaf053","article-title":"Semaglutide reprograms macrophages via the GLP-1R\/PPARG\/ACSL1 pathway to suppress papillary thyroid carcinoma growth","volume":"110","author":"Wang","year":"2025","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib110","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1210\/endo.142.5.8128","article-title":"Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate\/protein kinase A-dependent mechanism","volume":"142","author":"Wang","year":"2001","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.ejphar.2026.179406_bib111","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(25)00226-8","article-title":"Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial","volume":"13","author":"Wharton","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.ejphar.2026.179406_bib112","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJMoa2500969","article-title":"Oral semaglutide at a dose of 25 mg in adults with overweight or obesity","volume":"393","author":"Wharton","year":"2025","journal-title":"New Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ejphar.2026.179406_bib113","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib114","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Effectiveness and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.ejphar.2026.179406_bib115","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.ejphar.2026.179406_bib116","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1111\/dom.15083","article-title":"Control of human pancreatic beta cell kinome by glucagon-like peptide-1 receptor biased agonism","volume":"25","author":"Xiao","year":"2023","journal-title":"Diabetes Obes. Metabol."},{"issue":"1","key":"10.1016\/j.ejphar.2026.179406_bib117","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI0215595","article-title":"Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons","volume":"110","author":"Yamamoto","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2026.179406_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2026.179406_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116632","article-title":"Binding sites and design strategies for small molecule GLP-1R agonists","volume":"275","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"7657","key":"10.1016\/j.ejphar.2026.179406_bib120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ejphar.2026.179406_bib121","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signalling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926008885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T05:35:18Z","timestamp":1793079318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926008885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":119,"alternative-id":["S0014299926008885"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179406","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"179406"}}